Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review

Cover Page

Cite item

Full Text

Abstract

Pneumonia is clearly differentiated from other focal inflammatory lung diseases of non-infectious origin. A patient with community-acquired pneumonia (CAP) should receive antibacterial drugs no later than 4 hours after the diagnosis. Initial antibacterial therapy in CAP should be based on factors affecting the potential causative agents and the risk of drug-resistant microorganisms. Rational use of amoxicillin in terms of dose and frequency in CAP patients without severe comorbidities and risk factors for PES pathogens, the use of β-lactam in combination with a macrolide or moxifloxacin monotherapy in high-risk groups of patients is the most effective strategy of empirical antibacterial therapy.

About the authors

Andrey A. Zaytsev

Burdenko Main Military Clinical Hospital

Author for correspondence.
Email: a-zaicev-a@yandex.ru
ORCID iD: 0000-0002-0934-7313

D. Sci. (Med.), Prof., Burdenko Main Military Clinical Hospital

Russian Federation, Moscow

Igor A. Guchev

Nikita and Co LLC

Email: a-zaicev-a@yandex.ru

Cand. Sci. (Med.), Nikita and Co LLC

Russian Federation, Moscow

References

  1. Российское респираторное общество, Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. «Внебольничная пневмония у взрослых». Клинические рекомендации Министерства здравоохранения Российской Федерации. М., 2021 [Rossiiskoie respiratornoie obshchestvo, Mezhregional'naia assotsiatsiia po klinicheskoi mikrobiologii i antimikrobnoi khimioterapii. «Vnebol'nichnaia pnevmoniia u vzroslykh». Klinicheskiie rekomendatsii Ministerstva zdravookhraneniiya Rossiyskoi Federatsii. Moscow, 2021 (in Russian)].
  2. Авдеев С.Н., Белобородов В.Б., Белоцерковский Б.З., и др. Тяжелая внебольничная пневмония у взрослых. Клинические рекомендации Федерации анестезиологов и реаниматологов России. Анестезиология и реаниматология. 2022;(1):6-35 [Avdeev SN, Beloborodov VB, Belotserkovskiy BZ, et al. Severe community-acquired pneumonia in adults. Clinical recommendations from Russian Federation of Anaesthesiologists and Reanimatologists. Russian Journal of Anesthesiology and Reanimatology. 2022;(1):6-35 (in Russian)]. doi: 10.17116/anaesthesiology20220116
  3. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Int Care Med. 2023;49(6):615-32. doi: 10.1007/s00134-023-07033-8
  4. Ewig S, Kolditz M, Pletz M, et al. Management of Adult Community-Acquired Pneumonia and Prevention – Update 2021 – Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (OGP), the Austrian Society for Infectious and Tropical Diseases (OGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumologie (Stuttgart, Germany). 2021;75(9):665-729. doi: 10.1055/a-1497-0693
  5. NICE. Pneumonia in adults: diagnosis and management. Clinical guideline [CG191] Published: 03 December 2014 Last updated: 07 July 2022. NICE guidelines, 2022.
  6. Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25. doi: 10.1038/s41572-021-00259-0
  7. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-67. doi: 10.1164/rccm.201908-1581ST
  8. Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. New Engl J Med. 2015;373(5):415-27. doi: 10.1056/NEJMoa1500245
  9. Fan H, Zhou L, Lv J, et al. Bacterial coinfections contribute to severe COVID-19 in winter. Cell Res. 2023;33(7):562-4. doi: 10.1038/s41422-023-00821-3
  10. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2022. doi: 10.1093/cid/ciac724
  11. Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27(1):61-6. doi: 10.1016/j.cmi.2020.09.041
  12. Soltani S, Faramarzi S, Zandi M, et al. Bacterial coinfection among coronavirus disease 2019 patient groups: an updated systematic review and meta-analysis. New Microbes New Infect. 2021;43:100910.
  13. Kaal A, Snel L, Dane M, et al. Diagnostic yield of bacteriological tests and predictors of severe outcome in adult patients with COVID-19 presenting to the emergency department. Emerg Med J. 2021;38(9):685-91. doi: 10.1136/emermed-2020-211027
  14. Mandell LA, Zhanel GG, Rotstein C, et al. Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. Open Forum Infect Dis. 2022;9(3):ofac043. doi: 10.1093/ofid/ofac043
  15. Gadsby NJ, Musher DM. The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures. Clin Microbiol Rev. 2022;35(4):e0001522. doi: 10.1128/cmr.00015-22
  16. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016;62(7):817-23. doi: 10.1093/cid/civ1214
  17. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8(4):e60273. doi: 10.1371/journal.pone.0060273
  18. Синопальников А. Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой? Клиническая микробиология и антимикробная химиотерапия. 2019;21(1):27-38 [Sinopalnikov AI. Antibiotics and community-acquired lower respiratory tract infections. To whom? Which one? Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2019;21(1):27-38 (in Russian)].
  19. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. Available at: http://www.eucast.org. Accessed: 01.09.2023.
  20. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website. Available at: http://www.eucast.org. Accessed: 10.09.2023.
  21. Marchello C, Dale AP, Thai TN, et al. Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis. Ann Family Med. 2016;14(6):552-66.
  22. Guchev IA, Yu VL, Sinopalnikov A, et al. Management of nonsevere pneumonia in military trainees with the urinary antigen test for Streptococcus pneumoniae: an innovative approach to targeted therapy. Clin Infect Dis. 2005;40(11):1608-16. doi: 10.1086/429919
  23. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011;17 Suppl. 6(Suppl. 6):E1-59. doi: 10.1111/j.1469-0691.2011.03672.x
  24. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340-6. doi: 10.1136/thx.2010.143982
  25. Cilloniz C, Dominedo C, Torres A. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. Crit Care (London, England). 2019;23(1):79. doi: 10.1186/s13054-019-2371-3
  26. Ferrer M, Travierso C, Cilloniz C, et al. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE. 2018;13(1):e0191721. doi: 10.1371/journal.pone.0191721
  27. Odenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother. 2006;58(5):960-5. doi: 10.1093/jac/dkl356
  28. Lemmen SW, Hafner H, Klik S, et al. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy. 2003;49(1-2):33-5. doi: 10.1159/000069779
  29. McCurdy S, Keedy K, Lawrence L, et al. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial. Antimicrob Agents Chemother. 2020;64(3). doi: 10.1128/AAC.01949-19
  30. Utt E, Kantecki M, Cabezas-Camarero G, Esposito S. Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017–2019. J Glob Antimicrob Resist. 2023;33:360-7. doi: 10.1016/j.jgar.2023.05.002
  31. Kolotova ON, Kataeva LV, Bakshtanovskaya IV, et al. Resistance factors of klebsiella pneumoniae bacteria during COVID-19 pandemic. Russian Journal of Infection and Immunity. 2022;12(3):563-8. doi: 10.15789/2220-7619-rfo-1837
  32. Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2020:107663. doi: 10.1016/j.pharmthera.2020.107663
  33. Che Yusof R, Norhayati MN, Mohd Azman Y. Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: a systematic review and meta-analysis. Peer J. 2023;11:e15265. doi: 10.7717/peerj.15265
  34. Lavrinenko A, Kolesnichenko S, Kadyrova I, et al. Bacterial Co-Infections and Antimicrobial Resistance in Patients Hospitalized with Suspected or Confirmed COVID-19 Pneumonia in Kazakhstan. Pathogens. 2023;12(3). doi: 10.3390/pathogens12030370
  35. Зырянов С.К., Ченкуров М.С., Ивжиц М.А., и др. Исследование структуры сопутствующих заболеваний и этиологии внебольничной пневмонии у пациентов пожилого и старческого возраста. Клиническая микробиология и антимикробная химиотерапия. 2020;22(4):242-8 [Zyryanov SK, Chenkurov MS, Ivzhits MA, et al. Etiology of community-acquired pneumonia and prevalence of comorbidities in elderly patient population. Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2020;22(4):242-8 (in Russian)]. doi: 10.36488/cmac.2020.3.242248
  36. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153-60. doi: 10.1513/AnnalsATS.201407-305OC
  37. Webb BJ, Dascomb K, Stenehjem E, et al. Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score. Antimicrob Agents Chemother. 2016;60(5):2652-63. doi: 10.1128/AAC.03071-15
  38. Gadsby NJ, Helgason KO, Dickson EM, et al. Molecular diagnosis of Legionella infections – Clinical utility of front-line screening as part of a pneumonia diagnostic algorithm. J Infect. 2016;72(2):161-70. doi: 10.1016/j.jinf.2015.10.011
  39. Рачина С., Козлов Р., Шаль Е., и др. Структура бактериальных возбудителей внебольничной пневмонии в многопрофильных стационарах Смоленска. Пульмонология. 2014;1:5-18 [Rachina SA, Kozlov RS, Shal E, et al. A spectrum of causative bacterial pathogens in community-acquired pneumonia in multidisciplinary hospitals of smolensk. Pulmonologiia. 2011;1:5-18 (in Russian)].
  40. Зайцев А.А., Макаревич А.М., Паценко М.Б., Серговенцев А.А. Ошибки ведения больных с внебольничной пневмонией. Военно-медицинский журнал. 2022;343(12):24-37 [Zaitsev AA, Makarevich AM, Patsenko MB, Sergoventsev AA. Mistakes in the management of patients with community-acquired pneumonia. Voenno-meditsinskii zhurnal. 2022;343(12):24-37 (in Russian)]. doi: 10.52424/00269050_2022_343_12_24
  41. Marchello CS, Ebell MH, Dale AP, et al. Signs and Symptoms That Rule out Community-Acquired Pneumonia in Outpatient Adults: A Systematic Review and Meta-Analysis. J Am Board Fam Med. 2019;32(2):234-47. doi: 10.3122/jabfm.2019.02.180219
  42. Li F, Kong S, Xie K, et al. High ratio of C-reactive protein/procalcitonin predicts Mycoplasma pneumoniae infection among adults hospitalized with community acquired pneumonia. Scand J Clin Lab Investig. 2021;81(1):65-71. doi: 10.1080/00365513.2020.1858491
  43. Ren Y, Wang Y, Liang R, et al. Development and validation of a nomogram for predicting Mycoplasma pneumoniae pneumonia in adults. Sci Rep. 2022;12(1):21859. doi: 10.1038/s41598-022-26565-5
  44. Huo X, Xue X, Yuan S, et al. Early differential diagnosis between COVID-19 and mycoplasma pneumonia with chest CT scan. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(4):468-73 (in Chinese). doi: 10.3785/j.issn.1008-9292.2020.07.04
  45. Lim WS, Smith DL, Wise MP, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax. 2015;70(7):698-700. doi: 10.1136/thoraxjnl-2015-206881
  46. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl. 2:S27-72.
  47. Athlin S, Lidman C, Lundqvist A, et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect Dis. 2018;50(4):247-72. doi: 10.1080/23744235.2017.1399316
  48. Клинический протокол «Внебольничная пневмония у взрослых» (дата разработки/пересмотра: 2017 год (пересмотр в 2019 г.). Одобрен Объединенной комиссией по качеству медицинских услуг МЗ РК от 16.9.2022. Протокол №169 [Klinicheskii protokol «Vnebol'nichnaia pnevmoniia u vzroslykh» (data razrabotki/peresmotra: 2017 god (peresmotr v 2019 g.). Odobren Ob"iedinennoy komissiiei po kachestvu meditsinskikh uslug MZ RK ot 16.9.2022. Protokol №169 (in Russian)].
  49. Metlay JP, Waterer GW. Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Ann Internal Med. 2020;173(4):304-5. doi: 10.7326/M20-2189
  50. Setiawan E, Abdul-Aziz MH, Cotta MO, et al. Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients. Sci Rep. 2022;12(1):8930. doi: 10.1038/s41598-022-12627-1
  51. Twaddell SH, Baines KJ, Grainge C, Gibson PG. The Emerging Role of Neutrophil Extracellular Traps in Respiratory Disease. Chest. 2019;156(4):774-82. doi: 10.1016/j.chest.2019.06.012
  52. Bystrzycka W, Manda-Handzlik A, Sieczkowska S, et al. Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) Release. Int J Mol Sci. 2017;18(12). doi: 10.3390/ijms18122666
  53. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998;42(8):2060-5. doi: 10.1128/AAC.42.8.2060
  54. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006;42(1):73-81. doi: 10.1086/498520
  55. Zhao M, Chi Z, Pan X, et al. Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis. Int J Environ Res Public Health. 2022;19(8):4816. doi: 10.3390/ijerph19084816
  56. Du X, Han Y, Jian Y, et al. Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation. Clin Ther. 2021;43(11):1894-909 e1. doi: 10.1016/j.clinthera.2021.03.006
  57. Fogarty C, Torres A, Choudhri S, et al. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Int J Clin Pract. 2005;59(11):1253-9. doi: 10.1111/j.1368-5031.2005.00699.x
  58. Jones RN, Biedenbach DJ. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). Diagn Microbiol Infect Dis. 2003;45(4):273-8. doi: 10.1016/s0732-8893(03)00002-6
  59. Jones RN, Rubino CM, Bhavnani SM, et al. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 2003;47(1):292-6. doi: 10.1128/AAC.47.1.292-296.2003
  60. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 2001;47(6):811-8. doi: 10.1093/jac/47.6.811
  61. Bowker KE, Garvey MI, Noel AR, et al. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. J Antimicrob Chemother. 2013;68(5):1130-8. doi: 10.1093/jac/dks537
  62. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000;45(5):583-90. doi: 10.1093/jac/45.5.583
  63. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002;46(6):1746-54. doi: 10.1128/AAC.46.6.1746-1754.2002
  64. Garau J, Fritsch A, Arvis P, Read RC. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. J Chemother (Florence, Italy). 2010;22(4):264-6. doi: 10.1179/joc.2010.22.4.264
  65. Deshpande A, Klompas M, Guo N, et al. Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis. 2023;77(2):174-85. doi: 10.1093/cid/ciad196
  66. Stass H, Delesen H, Kubitza D, et al. Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Clin Drug Investig. 2010;30(5):279-87. doi: 10.1007/BF03256904
  67. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol. 2002;53(3):232-7. doi: 10.1046/j.0306-5251.2001.01557.x
  68. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet. 2001;40 Suppl. 1:33-8. doi: 10.2165/00003088-200140001-00005
  69. Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet. 2001;40 Suppl. 1:63-70. doi: 10.2165/00003088-200140001-00009
  70. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol. 2016;34(5):571-81. doi: 10.1016/j.clindermatol.2016.05.006
  71. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009;32(5):359-78. doi: 10.2165/00002018-200932050-00001
  72. Bonaldo G, Andriani LA, D'Annibali O, et al. Cardiovascular safety of macrolide and fluoroquinolone antibiotics: An analysis of the WHO database of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2019;28(11):1457-63. doi: 10.1002/pds.4873
  73. Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Drug Saf. 2019;42(4):529-38.doi: 10.1007/s40264-018-0751-2
  74. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R&D. 2012;12(2):71-100. doi: 10.2165/11634300-000000000-00000
  75. Fu L, Zhang X, Xiong J, et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study. Int J Infect Dis. 2023;135:101-8. doi: 10.1016/j.ijid.2023.08.001
  76. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015;148(7):1340-52e7. doi: 10.1053/j.gastro.2015.03.006
  77. Кузьменков А., Виноградова А.Г., Трушин И., и др. AMRmap-система мониторинга антибиотикорезистентности в России. Клиническая микробиология и антимикробная химиотерапия. 2021;23(2):198-204 [Kuzmenkov AYu, Vinogradova AG, Trushin IV, et al. AMRmap – antibiotic resistance surveillance system in Russia. Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2021;23(2):198-204 (in Russian)].
  78. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В., и др. Антибиотикорезистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014–2017». Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):230-7 [Ivanchik NV, Chagaryan АN, Sukhorukova МV, et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study «PEHASus 2014–2017». Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2019;21(3):230-7 (in Russian)]. doi: 10.36488/cmac.2019.3.230-237
  79. Suvorova MP, Sychev IN, Ignatenko OV, et al. The First Experience of Combined Use of Cefepime/Sulbactam and Aztreonam in ICU Patients with Nosocomial Infections Caused by Carbapenem-Resistant Gram-Negative Microorganisms Producing Class B and D Carbapenemases. Antibiot Chemother. 2023;67(11-12):36-45. doi: 10.37489/0235-2990-2022-67-11-12-36-45

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Using the CRB-65 scale to select the place of treatment for CAP.

Download (111KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies